Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial-Reference-Cited by-同舟云学术

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

Published:2019-03-29 Issue:6 Volume:83 Page:1175-1181
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Rivera Fernando^ORCID,Romero C.,Jimenez-Fonseca P.,Izquierdo-Manuel M.,Salud A.,Martínez E.,Jorge M.,Arrazubi V.,Méndez J. C.,García-Alfonso P.,Reboredo M.,Barriuso J.,Muñoz-Unceta N.,Jimeno R.,López C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03820-7.pdf

Reference15 articles.

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403

2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (TOGA): a phase 3, open-label, randomized controlled trial. Lancet 376(9742):687–697

3. Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A (2015) Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 17(12):996–1004

4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46

5. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI (2009) Capecitabine/cisplatin versus 5-fluorouracil/ cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non inferiority trial. Ann Oncol 20(4):666–673

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the treatment of human epidermal growth factor receptor 2-positive gastric cancer;International Journal of Clinical Oncology;2024-07-31

2. Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy;ESMO Gastrointestinal Oncology;2024-03

3. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report;World Journal of Clinical Cases;2024-02-06

4. Intestinal‐type Gastric Cancer;Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e;2024-01-23

5. A narrative review of the evolving landscape of the management of metastatic gastric cancer: the role of targeted therapies;Journal of Gastrointestinal Oncology;2023-12